Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

St. Jude's Integrity Micro DR

This article was originally published in The Gray Sheet

Executive Summary

PMA supplement approval is received for a revised version of the firm's 3500/3510 programmer software to activate the dynamic atrial overdrive feature in its Integrity Micro DR Model 5336 pacemaker, intended to reduce incidence of atrial fibrillation in patients paced to treat bradycardia. The feature can now be activated in new Integrity Micro DRs or previously implanted devices. The new software can also be used to activate DAO in the Integrity AFx DR Model 5342. On July 12, the company began shipping Integrity AFx DR devices with the DAO already activated, following premarket approval of the algorithm's inclusion in new pacers, announced July 11. The Integrity Micro DR was approved in December 2000 but required the PMA supplement to activate the DAO feature (1"The Gray Sheet" July 16, 2001, p. 12)

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015623

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel